Amyloid-β (Aβ) can deposit in or near the microvascular basement membrane (BM) in Alzheimer's disease (AD). We examined the effect of the Aβ binding antibody, lecanemab, on BM collagen IV (Col-IV) using viable brain microvessels (MV) isolated from human postmortem brain tissue with high AD neuropathologic change (ADNC=3, 16 females (mean 86 years), 11 males (mean 81 years)). MVs were exposed to lecanemab or isotype for 4 days and examined for Col-IV related outcomes: western blotting, capillary electrophoresis, RT-PCR, and degraded Col-IV. We find a subset of MV from some donors demonstrate Col-IV changes that could cause microvascular injury when exposed to lecanemab.
NationDASweeneyMDMontagneA, et al.Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
2.
WarehamLKBarattaRODel BuonoBJ, et al.Collagen in the central nervous system: contributions to neurodegeneration and promise as a therapeutic target. Mol Neurodegener2024; 19: 11.
3.
ZhaoNPessellAFChungTD, et al.Brain vascular basement membrane: comparison of human and mouse brain at the transcriptomic and proteomic levels. Matrix Biol2025; 139: 1–13.
4.
LoveSChalmersKInceP, et al.Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis2014; 3: 19–32.
5.
HampelHElhageAChoM, et al.Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain2023; 146: 4414–4424.
6.
HonigLSBarakosJDhaddaS, et al.ARIA In patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimers Dement (N Y)2023; 9: e12377.
7.
ScherlekAAKozbergMGNicollJAR, et al.Histopathological correlates of haemorrhagic lesions on ex vivo magnetic resonance imaging in immunized Alzheimer's disease cases. Brain Commun2022; 4: fcac021.
8.
SoderbergLJohannessonMNygrenP, et al.Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease. Neurotherapeutics2023; 20: 195–206.
9.
ReedMJDamodarasamyMPathanJL, et al.Increased hyaluronan and TSG-6 in association with neuropathologic changes of Alzheimer's disease. J Alzheimers Dis2019; 67: 91–102.
10.
DamodarasamyMKhaingZZHydeJ, et al.Viable human brain microvessels for the study of aging and neurodegenerative diseases. Microvasc Res2022; 140: 104282.
11.
MontineTJPhelpsCHBeachTG, et al.National institute on aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol2012; 123: 1–11.
12.
DoellingerJSchneiderAHoellerM, et al.Sample preparation by easy extraction and digestion (SPEED) - a universal, rapid, and detergent-free protocol for proteomics based on acid extraction. Mol Cell Proteomics2020; 19: 209–222.
13.
EricksonMAJohnsonRSDamodarasamyM, et al.Data-independent acquisition proteomic analysis of the brain microvasculature in Alzheimer's disease identifies major pathways of dysfunction and upregulation of cytoprotective responses. Fluids Barriers CNS2024; 21: 84.
14.
CaoYHuangMYMaoCH, et al.Structural changes in cerebral microvasculature induced by ferroptosis contribute to blood-brain barrier disruption in Alzheimer's disease: an autopsy study. Alzheimers Dement2025; 21: e70103.
15.
HawkesCAGathererMSharpMM, et al.Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-beta from the mouse brain. Aging Cell2013; 12: 224–236.
16.
SteinmanJSunHSFengZP. Microvascular alterations in Alzheimer's disease. Front Cell Neurosci2020; 14: 618986.
17.
KehletSNWillumsenNArmbrechtG, et al.Age-related collagen turnover of the interstitial matrix and basement membrane: implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS One2018; 13: e0194458.
18.
OveisgharanSYuLWangY, et al.Amyloid beta binding partners in the brain tissue of older adults. Alzheimers Dement2025; 21: e70882.
19.
PanwarPButlerGSJamrozA, et al.Aging-associated modifications of collagen affect its degradation by matrix metalloproteinases. Matrix Biol2018; 65: 30–44.
WellerROMasseyANewmanTA, et al.Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol1998; 153: 725–733.
22.
AncsinJBKisilevskyR. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem1999; 274: 7172–7181.
23.
CastilloGMLukitoWPeskindE, et al.Laminin inhibition of beta-amyloid protein (abeta) fibrillogenesis and identification of an abeta binding site localized to the globular domain repeats on the laminin a chain. J Neurosci Res2000; 62: 451–462.
24.
CotmanSLHalfterWColeGJ. Agrin binds to beta-amyloid (abeta), accelerates abeta fibril formation, and is localized to abeta deposits in Alzheimer's disease brain. Mol Cell Neurosci2000; 15: 183–198.
25.
DingYZhaoJZhangX, et al.Amyloid beta oligomers target to extracellular and intracellular neuronal synaptic proteins in Alzheimer's disease. Front Neurol2019; 10: 1140.
26.
ZahediK. Characterization of the binding of serum amyloid P to type IV collagen. J Biol Chem1996; 271: 14897–14902.
27.
RosenbergGAMun-BryceSWesleyM, et al.Collagenase-induced intracerebral hemorrhage in rats. Stroke1990; 21: 801–807.
28.
AlexdottirMSBourgonjeARKarsdalMA, et al.Serological biomarkers of intestinal collagen turnover identify early response to infliximab therapy in patients with crohn's disease. Front Med (Lausanne)2022; 9: 933872.
29.
JensenCSinkeviciuteDMadsenDH, et al.Granzyme B degraded type IV collagen products in serum identify melanoma patients responding to immune checkpoint blockade. Cancers (Basel)2020; 12: 2786.
30.
MundelTMKalluriR. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res2007; 74: 85–89.
31.
BelderCRSBocheDNicollJAR, et al.Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol2024; 23: 1025–1034.
32.
CummingsJL. Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: strategies and research directions. Neurotherapeutics2025; 22: e00570.
33.
SluijterJPSmeetsMBVelemaE, et al.Increased collagen turnover is only partly associated with collagen fiber deposition in the arterial response to injury. Cardiovasc Res2004; 61: 186–195.
34.
AsahiMWangXMoriT, et al.Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci2001; 21: 7724–7732.
35.
HorstmannSBudigLGardnerH, et al.Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr2010; 22: 966–972.
36.
BehlTKaurGSehgalA, et al.Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: pathophysiological and therapeutic perspectives. Int J Mol Sci2021; 22: 1413.
37.
BanksWAKovacAMorofujiY. Neurovascular unit crosstalk: pericytes and astrocytes modify cytokine secretion patterns of brain endothelial cells. J Cereb Blood Flow Metab2018; 38: 1104–1118.
38.
LeeSChungMLeeSR, et al.3D Brain angiogenesis model to reconstitute functional human blood-brain barrier in vitro. Biotechnol Bioeng2020; 117: 748–762.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
